TLR signaling in the gut in health and disease

Maria T Abreu, Masayuki Fukata, Moshe Arditi

Research output: Contribution to journalArticle

425 Citations (Scopus)

Abstract

The human intestine has evolved in the presence of diverse enteric microflora. TLRs convert the recognition of pathogen-associated molecules in the gut into signals for antimicrobial peptide expression, barrier fortification, and proliferation of epithelial cells. Healing of injured intestinal epithelium and clearance of intramucosal bacteria require the presence of intact TLR signaling. Nucleotide oligomerization domain (Nod)1 and Nod2 are additional pattern recognition receptors that are required for defense against invasive enteric pathogens. Through spatial and functional localization of TLR and Nod molecules, the normal gut maintains a state of controlled inflammation. By contrast, patients with inflammatory bowel disease demonstrate inflammation in response to the normal flora. A subset of these patients carry polymorphisms in TLR and CARD15/NOD2 genes. A better understanding of the delicate regulation of TLR and Nod molecules in the gut may lead to improved treatment for enteric infections and idiopathic inflammatory bowel diseases.

Original languageEnglish
Pages (from-to)4453-4460
Number of pages8
JournalJournal of Immunology
Volume174
Issue number8
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Nucleotides
Inflammatory Bowel Diseases
Health
Inflammation
Pattern Recognition Receptors
Intestinal Mucosa
Protein Sorting Signals
Intestines
Epithelial Cells
Bacteria
Infection
Genes
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Abreu, M. T., Fukata, M., & Arditi, M. (2005). TLR signaling in the gut in health and disease. Journal of Immunology, 174(8), 4453-4460.

TLR signaling in the gut in health and disease. / Abreu, Maria T; Fukata, Masayuki; Arditi, Moshe.

In: Journal of Immunology, Vol. 174, No. 8, 15.04.2005, p. 4453-4460.

Research output: Contribution to journalArticle

Abreu, MT, Fukata, M & Arditi, M 2005, 'TLR signaling in the gut in health and disease', Journal of Immunology, vol. 174, no. 8, pp. 4453-4460.
Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. Journal of Immunology. 2005 Apr 15;174(8):4453-4460.
Abreu, Maria T ; Fukata, Masayuki ; Arditi, Moshe. / TLR signaling in the gut in health and disease. In: Journal of Immunology. 2005 ; Vol. 174, No. 8. pp. 4453-4460.
@article{4c25da1a9a24453288395744f866a1c7,
title = "TLR signaling in the gut in health and disease",
abstract = "The human intestine has evolved in the presence of diverse enteric microflora. TLRs convert the recognition of pathogen-associated molecules in the gut into signals for antimicrobial peptide expression, barrier fortification, and proliferation of epithelial cells. Healing of injured intestinal epithelium and clearance of intramucosal bacteria require the presence of intact TLR signaling. Nucleotide oligomerization domain (Nod)1 and Nod2 are additional pattern recognition receptors that are required for defense against invasive enteric pathogens. Through spatial and functional localization of TLR and Nod molecules, the normal gut maintains a state of controlled inflammation. By contrast, patients with inflammatory bowel disease demonstrate inflammation in response to the normal flora. A subset of these patients carry polymorphisms in TLR and CARD15/NOD2 genes. A better understanding of the delicate regulation of TLR and Nod molecules in the gut may lead to improved treatment for enteric infections and idiopathic inflammatory bowel diseases.",
author = "Abreu, {Maria T} and Masayuki Fukata and Moshe Arditi",
year = "2005",
month = "4",
day = "15",
language = "English",
volume = "174",
pages = "4453--4460",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - TLR signaling in the gut in health and disease

AU - Abreu, Maria T

AU - Fukata, Masayuki

AU - Arditi, Moshe

PY - 2005/4/15

Y1 - 2005/4/15

N2 - The human intestine has evolved in the presence of diverse enteric microflora. TLRs convert the recognition of pathogen-associated molecules in the gut into signals for antimicrobial peptide expression, barrier fortification, and proliferation of epithelial cells. Healing of injured intestinal epithelium and clearance of intramucosal bacteria require the presence of intact TLR signaling. Nucleotide oligomerization domain (Nod)1 and Nod2 are additional pattern recognition receptors that are required for defense against invasive enteric pathogens. Through spatial and functional localization of TLR and Nod molecules, the normal gut maintains a state of controlled inflammation. By contrast, patients with inflammatory bowel disease demonstrate inflammation in response to the normal flora. A subset of these patients carry polymorphisms in TLR and CARD15/NOD2 genes. A better understanding of the delicate regulation of TLR and Nod molecules in the gut may lead to improved treatment for enteric infections and idiopathic inflammatory bowel diseases.

AB - The human intestine has evolved in the presence of diverse enteric microflora. TLRs convert the recognition of pathogen-associated molecules in the gut into signals for antimicrobial peptide expression, barrier fortification, and proliferation of epithelial cells. Healing of injured intestinal epithelium and clearance of intramucosal bacteria require the presence of intact TLR signaling. Nucleotide oligomerization domain (Nod)1 and Nod2 are additional pattern recognition receptors that are required for defense against invasive enteric pathogens. Through spatial and functional localization of TLR and Nod molecules, the normal gut maintains a state of controlled inflammation. By contrast, patients with inflammatory bowel disease demonstrate inflammation in response to the normal flora. A subset of these patients carry polymorphisms in TLR and CARD15/NOD2 genes. A better understanding of the delicate regulation of TLR and Nod molecules in the gut may lead to improved treatment for enteric infections and idiopathic inflammatory bowel diseases.

UR - http://www.scopus.com/inward/record.url?scp=17044385039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044385039&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 4453

EP - 4460

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -